Top

CAR T-cell Therapy for Central Nervous System Lymphoma

Journals by subject

Unlock free access to practice-relevant journal articles

Join our community of medical professionals and register now to access a handpicked selection of journal articles from Springer's Medical portfolio.

Editor's Choice | Journals

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest Journal Issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

Latest issues in Internal Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Cardiology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Diabetes & Endocrinology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Neurology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Oncology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Pediatrics

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Respiratory Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer.

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe.

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area.

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

Current Oncology Reports

Published in:

28-10-2024 | Lymphoma of the Central Nervous System | Review

CAR T-cell Therapy for Central Nervous System Lymphoma

Authors: Caroline Houillier, Sylvain Choquet

Published in: Current Oncology Reports | Issue 11/2024

Abstract

Purpose of Review

While anti-CD19 CAR T-cell therapy represents a major advance in systemic diffuse large B-cell lymphomas, central nervous system (CNS) lymphomas have been excluded from pivotal trials because of the fear of neurotoxicity. The purpose of this review was to assess the efficacy and tolerance of CAR T-cells in CNS lymphomas based on recently published studies.

Recent Findings

All the studies on CAR T-cell therapy for both primary and secondary CNS lymphomas reported high response rates (complete response rates ranging from 32 to 67%) in highly pre-treated patients. One-year PFS reached 40 to 60% in several studies. Neurotoxicity occurred in 36 to 68% of patients, including grade 3-4 neurotoxicity in 4.5 to 29% of patients.

Summary

CAR T-cell therapy appears to be a very promising treatment in CNS lymphomas, with efficacy results close to those observed in systemic lymphomas. The toxicity profile, notably regarding neurotoxicity, is reassuring and should not prevent the development of CAR T-cells in the disease.

Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020;94:e1027-39. https://doi.org/10.1212/WNL.0000000000008900.CrossRefPubMedPubMedCentral

Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2023;25(1):37-53. https://doi.org/10.1093/neuonc/noac196.CrossRefPubMed

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31-42. https://doi.org/10.1016/S1470-2045(18)30864-7.CrossRefPubMed

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380:45-56. https://doi.org/10.1056/NEJMoa1804980.CrossRefPubMed

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294-308. https://doi.org/10.1016/S0140-6736(22)00662-6.CrossRefPubMed

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386:640-54. https://doi.org/10.1056/NEJMoa2116133.CrossRefPubMed

Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111:646-54. https://doi.org/10.1093/jnci/djz017.CrossRefPubMed

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404-19. https://doi.org/10.1158/2159-8290.CD-17-0698.CrossRefPubMedPubMedCentral

Belin C, Devic P, Ayrignac X, Dos Santos A, Paix A, Sirven-Villaros L, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020;10:18997. https://doi.org/10.1038/s41598-020-76055-9.CrossRefPubMedPubMedCentral

10.

Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133:2212-21. https://doi.org/10.1182/blood-2018-12-893396.CrossRefPubMed

11.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and neurologic toxicity Associated with Immune Effector cells. Biol Blood Marrow Transpl. 2019;25:625-38. https://doi.org/10.1016/j.bbmt.2018.12.758.CrossRef

12.

Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, et al. Anti-CD19 CAR T cells in CNS diffuse Large-B-Cell lymphoma. N Engl J Med. 2017;377:783-4. https://doi.org/10.1056/NEJMc1704610.CrossRefPubMed

13.

Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134:860-6. https://doi.org/10.1182/blood.2019001694.CrossRefPubMedPubMedCentral

14.

Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021;5:5626-30. https://doi.org/10.1182/bloodadvances.2021005292.CrossRefPubMedPubMedCentral

15.

Siddiqi T, Wang X, Blanchard MS, Wagner JR, Popplewell LL, Budde LE, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021;5:4059-63. https://doi.org/10.1182/bloodadvances.2020004106.CrossRefPubMedPubMedCentral

16.

Alcantara M, Houillier C, Blonski M, Rubio MT, Willems L, Rascalou AW, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022;139:792-6. https://doi.org/10.1182/blood.2021012932.CrossRefPubMedPubMedCentral

17.

Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139:2306-15. https://doi.org/10.1182/blood.2021014738.CrossRefPubMedPubMedCentral

18.

Choquet S, Soussain C, Morel V, Ursu R. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma. Real-life results of the LOC network. Am J Hematol. 2024;99:1240-9. https://doi.org/10.1002/ajh.27316.CrossRefPubMed

19.

Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, et al. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol. 2023;25:2239-49. https://doi.org/10.1093/neuonc/noad118.CrossRefPubMedPubMedCentral

20.

Nayak L, Chukwueke UN, Meehan C, Redd R, Hogan S, Quant Lee E, et al. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL). J Clin Oncol. 2024. https://doi.org/10.1200/JCO.2024.42.CrossRef

21.

Yu W, Huang L, Mei H, Li Y, Niu T, Zou D, et al. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China. J Immunother Cancer. 2024;12:e008553.CrossRefPubMedPubMedCentral

22.

Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, et al. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023;16:111. https://doi.org/10.1186/s13045-023-01508-3.CrossRefPubMedPubMedCentral

23.

Ayuk F, Gagelmann N, von Tresckow B, Wulf G, Rejeski K, Stelljes M, et al. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. Blood Adv. 2023;7:5316-9. https://doi.org/10.1182/bloodadvances.2023010336.CrossRefPubMedPubMedCentral

24.

Saidy AO, Fuhrmann S, Peczynski C, Michel E, Galimard, et al. Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition. Blood. 2023;142:1031. https://doi.org/10.1182/blood-2023-174883.CrossRef

25.

Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek AE, et al. Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: a multicenter analysis. Am J Hematol. 2024;99:1624-7. https://doi.org/10.1002/ajh.27354.CrossRefPubMed

26.

Cook MR, Dorris CS, Makambi KH, Munshi PN, Donato M, Rowley S, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7:32-9. https://doi.org/10.1182/bloodadvances.2022008525.CrossRefPubMed

27.

Elgohary G, Yang Y, Gergis M, Yi D, Gergis U. Chimeric Antigen Receptor T - cell therapy for large B-Cell lymphoma patients with central nervous system involvement, a systematic review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2024;24:e142-51. https://doi.org/10.1016/j.clml.2023.12.012.CrossRefPubMed

28.

Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145-54. https://doi.org/10.1038/s41591-022-01969-y.CrossRefPubMedPubMedCentral

29.

Hernandez Tost H, Weiss N, Choquet S, Ribeiro M, Birzu C, Le Guennec L. Neurotoxicity in patients with CNS lymphomas treated with CAR-T cell therapy. A LOC network study. Neuro Oncol. 2023;25:ii7-8. https://doi.org/10.1093/neuonc/noad137.019.CrossRefPubMedCentral

30.

Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, et al. Neurological toxicities associated with chimeric antigen receptor T cell therapy. Brain. 2019;142:1334-48. https://doi.org/10.1093/brain/awz053.CrossRefPubMed

31.

Lacan C, Caron J, Tarantino N, Fouquet B, Cherai M, Parizot C, et al. CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes. Haematologica. 2023;108:3485-90. https://doi.org/10.3324/haematol.2023.282875.CrossRefPubMedPubMedCentral

32.

Schenone L, Houillier C, Tanguy ML, Choquet S, Agbetiafa K, Ghesquières H, et al. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network. Bone Marrow Transpl. 2022;57(6):966-74.CrossRef

33.

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510-23. https://doi.org/10.1016/S2352-3026(17)30174-6.CrossRefPubMed

34.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019;37:823-33. https://doi.org/10.1200/JCO.18.00306.CrossRefPubMed

35.

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121-30. https://doi.org/10.1016/j.ejca.2019.05.024.CrossRefPubMed

36.

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, et al. Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory primary CNS lymphoma or primary intraocular lymphoma: a Multicenter prospective proof of Concept Phase II study of the French Oculo-Cerebral Lymphoma (LOC) network and the Lymphoma Study Association (LYSA). Ann Oncol. 2019;30:621-8. https://doi.org/10.1093/annonc/mdz032.CrossRefPubMed

37.

Hoang-Xuan K, Houot R, Soussain C, Blonski M, Schmitt A, Delwail V, et al. First results of the Acsé Pembrolizumab Phase II in the primary CNS lymphoma (PCNSL) cohort. Blood. 2020;136:15-6. https://doi.org/10.1182/blood-2020-141773.CrossRef

38.

Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071-3. https://doi.org/10.1182/blood-2017-01-764209.CrossRefPubMedPubMedCentral

39.

Cao Y, Lu W, Sun R, Jin X, Cheng L, He X, et al. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination with Nivolumab are safe and effective against Relapsed/Refractory B-Cell non-hodgkin Lymphoma. Front Oncol. 2019;9:767. https://doi.org/10.3389/fonc.2019.00767.CrossRefPubMedPubMedCentral

40.

Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139:1026-38. https://doi.org/10.1182/blood.2021012634.CrossRefPubMedPubMedCentral

41.

Otáhal P, Průková D, Král V, Fabry M, Vočková P, Latečková L, et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology. 2015;5:e1115940. https://doi.org/10.1080/2162402X.2015.1115940.CrossRefPubMedPubMedCentral

42.

Ping N, Qu C, Li M, Kang L, Kong D, Chen X, et al. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma. Ann Transl Med. 2022;10:298. https://doi.org/10.21037/atm-22-20.CrossRefPubMedPubMedCentral

43.

Liu M, Deng H, Mu J, Li Q, Pu Y, Jiang Y, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-hodgkin lymphoma. Cancer Sci. 2021;112:2642-51. https://doi.org/10.1111/cas.14915.CrossRefPubMedPubMedCentral

44.

Liu M, Wang X, Li Z, Zhang R, Mu J, Jiang Y, et al. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. Cancer Sci. 2020;111:4051-60. https://doi.org/10.1111/cas.14638.CrossRefPubMedPubMedCentral

45.

Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195:388-98. https://doi.org/10.1111/bjh.17673.CrossRefPubMedPubMedCentral

46.

Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4:3123-7. https://doi.org/10.1182/bloodadvances.2020002328.CrossRefPubMedPubMedCentral

Title: CAR T-cell Therapy for Central Nervous System Lymphoma
Authors: Caroline Houillier
Sylvain Choquet
Publication date: 28-10-2024
Publisher: Springer US
Keywords: Lymphoma of the Central Nervous System
CAR T-Cell Therapy
Lymphoma
Central Nervous System Cancer
Central Nervous System Cancer
Published in: Current Oncology Reports / Issue 11/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01609-3

Ovarian cancer prevention: what do we know

Ovarian Cancer
Review

Traditional Chinese Medicine Herbs for Breast Cancer Prevention and Survival: A Narrative Review of Epidemiological Studies from Taiwan

Breast Cancer
REVIEW

Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma

Open Access
Cytostatic Therapy
REVIEW

How to Identify and Manage High-Risk Smoldering Multiple Myeloma

Multiple Myeloma
REVIEW

Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer

Endometrial Cancer
REVIEW

The difficult airway in patients with cancer

Airway Management
Review

Keynote series | Spotlight on menopause

Springer Medicine

CAR T-cell Therapy for Central Nervous System Lymphoma

Unlock free access to practice-relevant journal articles

Looking for something specific?

About journals on Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content